Enliven Therapeutics, Inc. - 8-K Filing
Enliven Therapeutics reported $452.4 million in cash, cash equivalents, and marketable securities as of March 31, 2026, providing a cash runway into the first half of 2029. The company incurred a net loss of $23.6 million for Q1 2026, down from $28.5 million in Q1 2025, with R&D expenses at $20.7 million and G&A expenses at $7.1 million. The company plans to initiate the Phase 3 trial of ELVN-001 in the second half of 2026. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $ELVN